Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Market Closed 02-14 16:00:00 EST

337.20

-14.51

-4.13%

盘后337.20

+0.000.00%

18:27 EST

High354.49	Low334.67	Vol372.40K
Open353.98	D1 Closing351.71	Amplitude5.64%
Mkt Cap7.35B	Tradable Cap3.75B	Total Shares21.81M
T/O128.03M	T/O Rate3.35%	Tradable Shares11.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":337.2,"timestamp":1739566800000,"preClose":351.71,"halted":0,"volume":372402,"hourTrading":{"tag":"盘后","latestPrice":337.2,"preClose":337.2,"latestTime":"18:27 EST","volume":9954,"amount":3356512.4702,"timestamp":1739575652636},"delay":0,"floatShares":11127261,"shares":21810407,"eps":-25.017162,"marketStatus":"Market Closed","change":-14.51,"latestTime":"02-14 16:00:00 EST","open":353.98,"high":354.49,"low":334.67,"amount":128029833.8694,"amplitude":0.056353,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-25.017162,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":351.71,"preHourTrading":{"tag":"盘前","latestPrice":353.91,"preClose":351.71,"latestTime":"09:29 EST","volume":1111,"amount":392698.11514999997,"timestamp":1739543375728},"postHourTrading":{"tag":"盘后","latestPrice":337.2,"preClose":337.2,"latestTime":"18:27 EST","volume":9954,"amount":3356512.4702,"timestamp":1739575652636},"volumeRatio":1.247852124704073,"impliedVol":0.7842,"impliedVolPercentile":0.8446},"requestUrl":"/m/hq/s/MDGL","defaultTab":"news","newsList":[{"id":"2511284826","title":"John Paulson's Strategic Moves: Thryv Holdings Inc. Takes Center Stage with a 2.04% Portfolio Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2511284826","media":"GuruFocus.com","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511284826?lang=en_us&edition=fundamental","pubTime":"2025-02-15 10:35","pubTimestamp":1739586933,"startTime":"0","endTime":"0","summary":"Exploring the Latest 13F Filing and Investment Strategies. GuruFocus has detected 4 Warning Signs with MDGL.John Paulson  added a total of 1 stock, among them:. The most significant addition was Alphabet Inc , with 10,000 shares, accounting for 0.12% of the portfolio and a total value of $1.9 million.The most notable increase was Thryv Holdings Inc , with an additional 2,280,000 shares, bringing the total to 4,280,000 shares. This adjustment represents a significant 114% increase in share count, a 2.04% impact on the current portfolio, and a total value of $63,344,000.John Paulson  completely exited 3 of the holdings in the fourth quarter of 2024, as detailed below:. Tellurian Inc : John Paulson  sold all 30,000,000 shares, resulting in a -2.04% impact on the portfolio.Southwestern Energy Co : John Paulson  liquidated all 2,200,000 shares, causing a -1.1% impact on the portfolio.The holdings are mainly concentrated in 4 of all the 11 industries: Healthcare, Basic Materials, Financial S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/john-paulsons-strategic-moves-thryv-023533001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999014914.USD","LU1674673691.USD","IE00B1BXHZ80.USD","MDGL","LU2098885051.SGD","PPTA","SG9999015945.SGD","LU0170899867.USD","AAMI","USJW.SI","LU1670628061.USD","LU1670627923.USD","LU0106261372.USD","QID","LU0648000940.SGD","LU1066051498.USD","LU0345769128.USD","BHC","SQQQ","LU2362540622.SGD","LU1791710400.SGD","LU2191332357.HKD","NG","LU1852331112.SGD","TQQQ","NQmain","LU1119994496.HKD","LU2242649171.HKD","BK4581",".IXIC","LU0882574139.USD","NVIW.SI","QLD","TSYW.SI","BK4585","GOOGL","PSQ","LU1267930730.SGD","MNQmain","USAW.SI","THRY","SSI","SG9999000418.SGD","LU1551013425.SGD","LU1043141396.HKD","SG9999015978.USD","LU0256863811.USD","LU2326559502.SGD","TELL"],"gpt_icon":1},{"id":"2511328126","title":"U.S. RESEARCH ROUNDUP-Airbnb, CVS Health, Roku","url":"https://stock-news.laohu8.com/highlight/detail?id=2511328126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511328126?lang=en_us&edition=fundamental","pubTime":"2025-02-14 14:53","pubTimestamp":1739515988,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Airbnb, CVS Health, Roku Feb 14 (Reuters) - Feb 14 (Reuters) Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nL4N3P50L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DE","LU1169589451.USD","EEFT","BK4566","SG9999002521.SGD","TWLO","FROG","BK4535","ABNB","MKSI","PANW","PCOR","LU2413666426.HKD","PEGA","DXCM","BK4547","GXO","LU0868494708.USD","LU2125909247.SGD","MDGL","ALB","IE00B19Z8X17.USD","SN","TYL","RSG","WH","BK4507","SG9999014005.SGD","IDYA","IE00BMPRXN33.USD","WEN","ALNY","CVS","LU1861215975.USD","ROKU","COIN","IE0031619046.USD","HRI","LU0289739343.SGD","LU0354030438.USD","LU1718418525.SGD","LU1059921491.USD","PAYC","DLR","LU0476273544.USD","USFD","CROX","GPN","BRKR","RARE"],"gpt_icon":1},{"id":"2511602562","title":"Madrigal Pharmaceuticals (MDGL) Gets a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2511602562","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511602562?lang=en_us&edition=fundamental","pubTime":"2025-02-13 13:44","pubTimestamp":1739425455,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-gets-a-buy-from-evercore-isi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-mdgl-gets-a-buy-from-evercore-isi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MDGL","BK4585","BK4139"],"gpt_icon":0},{"id":"2510379699","title":"Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510379699","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510379699?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:00","pubTimestamp":1739365200,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., Feb. 12, 2025  -- Madrigal Pharmaceuticals, Inc.  announced today that it will release its fourth-quarter and full-year 2024 financial results onWednesday, Feb. 26, 2025, prior to the open of the U.S.financial markets.Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.The live webcast may be accessed at the Investor Relations section of theMadrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast.The webcast will be available approximately two hours after the live webcast.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-release-fourth-quarter-130000944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","MDGL","BK4585","BK4588","BK4181","HST","BK4139"],"gpt_icon":0},{"id":"2507865534","title":"AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2507865534","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507865534?lang=en_us&edition=fundamental","pubTime":"2025-01-29 23:15","pubTimestamp":1738163700,"startTime":"0","endTime":"0","summary":"Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week data from a mid-stage study of its lead product candidate, efruxifermin , for liver disease. The phase IIb SYMMETRY study evaluated two doses of EFX  compared with a placebo in patients with biopsy-confirmed compensated cirrhosis , Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis .Per the data readout, in patients with both baseline and week 96 biopsies, 39% of those receiving 50mg EFX experienced cirrhosis reversal without MASH worsening, compared to 15% in the placebo group.In the Intent-to-Treat analysis, which considered missing week 96 biopsies as treatment failures, 29% of the 50mg EFX group achieved cirrhosis reversal without MASH worsening, compared to about 12% in the placebo group.The SYMMETRY study highlights the advantages of extended EFX treatment for patients with compensated cirrhosis, as evidenced by more than a twofold ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akro-stock-doubles-week-lead-151500816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0154236417.USD","IE00BZ1G4Q59.USD","EFX","BK4532","BK4505","IE00BKVL7J92.USD","LU1093756325.SGD","BK4007","MDGL","BK4139","BK4588","BK4599","NVO","ETNB","BK4123","AKRO","LU1093756168.USD"],"gpt_icon":1},{"id":"2507868289","title":"David Lebowitz’s Buy Recommendation for Madrigal Pharmaceuticals Amid Positive Outlook and Promising Future Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2507868289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507868289?lang=en_us&edition=fundamental","pubTime":"2025-01-29 19:46","pubTimestamp":1738151200,"startTime":"0","endTime":"0","summary":"Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday. David Lebowitz has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/david-lebowitzs-buy-recommendation-for-madrigal-pharmaceuticals-amid-positive-outlook-and-promising-future-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/david-lebowitzs-buy-recommendation-for-madrigal-pharmaceuticals-amid-positive-outlook-and-promising-future-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2506137905","title":"B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2506137905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506137905?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:16","pubTimestamp":1738070176,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-financial-keeps-their-hold-rating-on-madrigal-pharmaceuticals-mdgl-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-financial-keeps-their-hold-rating-on-madrigal-pharmaceuticals-mdgl-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2506358407","title":"Akero cirrhosis data positive for Madrigal, says Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2506358407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506358407?lang=en_us&edition=fundamental","pubTime":"2025-01-28 04:30","pubTimestamp":1738009821,"startTime":"0","endTime":"0","summary":"Piper Sandler reiterated an Overweight rating and $336 price target on Madrigal Pharmaceuticals (MDGL) after Akero Therapeutics (AKRO) announced “p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/akero-cirrhosis-data-positive-for-madrigal-says-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/akero-cirrhosis-data-positive-for-madrigal-says-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4505","MDGL","AKRO","BK4139"],"gpt_icon":0},{"id":"2506586587","title":"Positive Outlook for Madrigal Pharmaceuticals Driven by Rezdiffra’s Potential and Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2506586587","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506586587?lang=en_us&edition=fundamental","pubTime":"2025-01-28 02:45","pubTimestamp":1738003510,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Liisa Bayko...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-madrigal-pharmaceuticals-driven-by-rezdiffras-potential-and-market-opportunity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-madrigal-pharmaceuticals-driven-by-rezdiffras-potential-and-market-opportunity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDGL","BK4588","BK4585"],"gpt_icon":0},{"id":"2505004401","title":"Exploring Three High Growth Tech Stocks in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2505004401","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505004401?lang=en_us&edition=fundamental","pubTime":"2025-01-24 02:02","pubTimestamp":1737655373,"startTime":"0","endTime":"0","summary":"The United States market has shown robust performance with a 2.4% increase over the last week and a remarkable 25% rise over the past year, while earnings are projected to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong revenue growth potential and innovative capabilities to capitalize on these favorable market conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.Operations: Five9, Inc. generates revenue primarily from its Internet Software & Services segment, amounting to $1 billion. The company focuses on delivering cloud-based solutions for contact centers across various regions including the United States and India.Overview: Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for treating non-alcoholic steatohepatitis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-180253171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UBCP","BK4526","BK4509","MDGL","FIVN","TUYA","BK4139","BK4505","BK4585","BK4023","BK4211","BK4588"],"gpt_icon":0},{"id":"2505242153","title":"Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making","url":"https://stock-news.laohu8.com/highlight/detail?id=2505242153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505242153?lang=en_us&edition=fundamental","pubTime":"2025-01-21 18:22","pubTimestamp":1737454976,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals’ ($MDGL) product, REZDIFFRA, garnered impressive Q4 sales with a compelling 61% growth on a mere 4% market penetration. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/madrigal-pharmaceuticals-treatment-could-be-a-blockbuster-in-the-making?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/madrigal-pharmaceuticals-treatment-could-be-a-blockbuster-in-the-making?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","MDGL"],"gpt_icon":0},{"id":"2504826163","title":"Why Madrigal Pharmaceuticals Stock Was Plummeting This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2504826163","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504826163?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:28","pubTimestamp":1737116880,"startTime":"0","endTime":"0","summary":"That was unexpected, as the company actually had some encouraging news to deliver.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/01/17/why-madrigal-pharmaceuticals-stock-was-plummeting/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","MDGL","BK4139","BK4588"],"gpt_icon":0},{"id":"2503375998","title":"Piper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503375998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503375998?lang=en_us&edition=fundamental","pubTime":"2025-01-16 19:47","pubTimestamp":1737028064,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-madrigal-pharmaceuticals-mdgl-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-madrigal-pharmaceuticals-mdgl-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2503962979","title":"Bank of America Securities Reaffirms Their Sell Rating on Madrigal Pharmaceuticals (MDGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503962979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503962979?lang=en_us&edition=fundamental","pubTime":"2025-01-16 19:17","pubTimestamp":1737026231,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-sell-rating-on-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-sell-rating-on-madrigal-pharmaceuticals-mdgl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL","BAC"],"gpt_icon":0},{"id":"2503562119","title":"MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2503562119","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503562119?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:41","pubTimestamp":1736952060,"startTime":"0","endTime":"0","summary":"Shares of Madrigal Pharmaceuticals MDGL lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra , a once-daily, oral and liver-directed THR-β agonist.Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis . Subsequently, the drug became the first and only FDA-approved therapy that targets the underlying causes of NASH.In the past three months, Madrigal shares have gained 27.1% against the industry’s 11.7% decline.Madrigal reported preliminary fourth-quarter 2024 revenues from Rezdiffra sales in the $100-$103 million range.For the full year, MDGL announced preliminary revenues in the $177-$180 million band from the drug’s sales since its launch in April 2024. Per the company, more than 11,800 patients are on Rezdiffra treatment as of year-end ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mdgl-stock-down-10-disappointing-144100165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDGL"],"gpt_icon":0},{"id":"2503520484","title":"Madrigal Pharmaceuticals’ Strong Market Position and Promising Outlook Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2503520484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503520484?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:05","pubTimestamp":1736859939,"startTime":"0","endTime":"0","summary":"Jefferies analyst Akash Tewari has maintained their bullish stance on MDGL stock, giving a Buy rating today. Akash Tewari has given his Buy rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-strong-market-position-and-promising-outlook-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/madrigal-pharmaceuticals-strong-market-position-and-promising-outlook-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2503527662","title":"Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2503527662","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503527662?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:56","pubTimestamp":1736859360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2025 07:56 ET (12:56 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"gpt_icon":0},{"id":"2503523093","title":"Madrigal Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $400 From $390","url":"https://stock-news.laohu8.com/highlight/detail?id=2503523093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503523093?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:16","pubTimestamp":1736853366,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nAZN33B2WY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2503056932","title":"Positive Outlook and Buy Rating for Madrigal Pharmaceuticals Driven by Strong Rezdiffra Performance and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2503056932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503056932?lang=en_us&edition=fundamental","pubTime":"2025-01-14 09:08","pubTimestamp":1736816884,"startTime":"0","endTime":"0","summary":"Citi analyst David Lebowitz maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) yesterday and set a price target of $378.0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-and-buy-rating-for-madrigal-pharmaceuticals-driven-by-strong-rezdiffra-performance-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-and-buy-rating-for-madrigal-pharmaceuticals-driven-by-strong-rezdiffra-performance-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0},{"id":"2503553397","title":"Madrigal Pharmaceuticals price target lowered to $154 from $155 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2503553397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503553397?lang=en_us&edition=fundamental","pubTime":"2025-01-14 04:40","pubTimestamp":1736800808,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $154 from $155 and keeps an Underperform rating on the shares after the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-154-from-155-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-154-from-155-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.2288},{"period":"3month","weight":0.1685},{"period":"6month","weight":0.3444},{"period":"1year","weight":0.5174},{"period":"ytd","weight":0.0928}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.038123},{"month":2,"riseRate":0.777778,"avgChangeRate":0.079163},{"month":3,"riseRate":0.25,"avgChangeRate":-0.038862},{"month":4,"riseRate":0.5,"avgChangeRate":0.008688},{"month":5,"riseRate":0.375,"avgChangeRate":0.168822},{"month":6,"riseRate":0.625,"avgChangeRate":0.024173},{"month":7,"riseRate":0.125,"avgChangeRate":-0.088753},{"month":8,"riseRate":0.555556,"avgChangeRate":0.058165},{"month":9,"riseRate":0.333333,"avgChangeRate":0.13282},{"month":10,"riseRate":0.666667,"avgChangeRate":0.070394},{"month":11,"riseRate":0.555556,"avgChangeRate":0.062808},{"month":12,"riseRate":0.444444,"avgChangeRate":0.416281}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}